Drug Profile
Cabozantinib - Exelixis/Ipsen
Alternative Names: BMS-907351; CABOMETYX; Cabometyx; Cabozantinib s-malate; Cometriq; XL-184Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Exelixis
- Developer Bristol-Myers Squibb; Centre Francois Baclesse; Dana-Farber Cancer Institute; Duke University Medical Center; Emory University; Exelixis; Ipsen; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); Roche; Swedish Orphan Biovitrum; Takeda; University of California at Irvine; University of Kentucky
- Class Amides; Anilides; Antineoplastics; Cyclopropanes; Fluorine compounds; Quinolines; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c ret inhibitors; Proto-oncogene protein c-met inhibitors; TIE 2 receptor antagonists; TrkB receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Liver cancer; Renal cell carcinoma; Thyroid cancer
- Phase III Neuroendocrine tumours; Non-small cell lung cancer; Prostate cancer
- Phase II Adenocarcinoma; Adrenocortical carcinoma; Bone metastases; Brain metastases; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Gastrointestinal cancer; Head and neck cancer; Malignant fibrous histiocytoma; Malignant melanoma; Merkel cell carcinoma; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Phaeochromocytoma; Urogenital cancer; Uveal melanoma
- Phase I/II Multiple myeloma; Solid tumours
- No development reported Acute myeloid leukaemia; Astrocytoma; Cancer; Colorectal cancer; Glioblastoma
Most Recent Events
- 06 Feb 2024 Ipsen announces intention to file regulatory submission for Castrate-resistant prostate cancer(Combination therapy, Hormone-refractory, Metaststic disease, Second-line therapy or greater) in Japan in 2024 (Takeda pipeline, November 2022)
- 25 Jan 2024 Updated efficacy data from the phase III CheckMate 9ER trial in Renal cell carcinoma presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
- 25 Jan 2024 Efficacy and adverse events data from a phase I/Ib trial in Urogenital cancer were released by Exelixis